Palo Alto, CA, United States of America

Sreenivasarao Vepachedu


Average Co-Inventor Count = 5.7

ph-index = 2

Forward Citations = 15(Granted Patents)


Location History:

  • Hinsdale, IL (US) (2003)
  • Palo Alto, CA (US) (2004)

Company Filing History:


Years Active: 2003-2004

Loading Chart...
3 patents (USPTO):

Title: Sreenivasarao Vepachedu: Innovator in Pharmaceutical Research

Introduction

Sreenivasarao Vepachedu is a notable inventor based in Palo Alto, CA. He has made significant contributions to the field of pharmaceutical research, particularly in the development of compounds that inhibit MRP1, a protein associated with drug resistance in cancer treatment. With a total of 3 patents, his work has the potential to impact therapeutic strategies for resistant neoplasms.

Latest Patents

One of his latest patents is titled "Methods and compounds for inhibiting MRP1." This invention relates to a method of inhibiting MRP1 in mammals by administering an effective amount of a specific compound. Another significant patent is "Tricyclic compounds as MRP1-inhibitors," which describes compounds that are useful for inhibiting resistant neoplasms where the resistance is conferred by MRP1.

Career Highlights

Sreenivasarao Vepachedu is currently employed at Eli Lilly and Company, a leading global pharmaceutical company. His work focuses on innovative solutions to combat drug resistance in cancer therapies. His research has contributed to the understanding of how certain compounds can be utilized to enhance the effectiveness of existing treatments.

Collaborations

Throughout his career, Sreenivasarao has collaborated with esteemed colleagues, including Peter Ambrose Lander and Rosanne Bonjouklian. These collaborations have fostered a productive environment for innovation and research in the pharmaceutical field.

Conclusion

Sreenivasarao Vepachedu's contributions to pharmaceutical research, particularly in the area of MRP1 inhibition, highlight his role as an influential inventor. His patents and ongoing work at Eli Lilly and Company continue to pave the way for advancements in cancer treatment.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…